PubRank

Antoni Ribas

Author PubWeight™ 381.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011 45.46
2 Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 36.57
3 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010 18.69
4 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 18.08
5 Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010 16.12
6 Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012 13.17
7 RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011 10.77
8 Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012 10.39
9 Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010 10.09
10 Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015 8.64
11 Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012 8.13
12 RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012 6.93
13 Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2014 5.65
14 Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010 5.57
15 Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014 5.43
16 Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012 4.94
17 PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011 4.80
18 Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014 4.71
19 Tumor immunotherapy directed at PD-1. N Engl J Med 2012 4.43
20 Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013 3.51
21 Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov 2014 2.74
22 HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009 2.56
23 A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med 2011 2.54
24 Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009 2.53
25 Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013 2.51
26 BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012 2.48
27 Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2012 2.45
28 Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 2011 2.42
29 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
30 The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 2012 2.31
31 Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013 2.30
32 Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov 2012 2.27
33 Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 2012 2.21
34 BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012 2.14
35 Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013 2.13
36 The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010 2.02
37 Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011 1.89
38 Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003 1.83
39 A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med 2008 1.77
40 A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 2013 1.75
41 Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 2005 1.74
42 Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov 2013 1.68
43 CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res 2014 1.66
44 Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A 2011 1.61
45 T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res 2008 1.61
46 Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 2008 1.56
47 Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 2014 1.55
48 A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J 2014 1.51
49 A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006 1.48
50 A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 2011 1.45
51 Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol 2004 1.44
52 CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011 1.42
53 Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009 1.38
54 Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res 2006 1.37
55 Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A 2010 1.36
56 Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc 2009 1.34
57 Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol 2011 1.34
58 Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med 2011 1.33
59 Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 2009 1.31
60 CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 2009 1.28
61 Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008 1.25
62 A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010 1.24
63 T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 2003 1.24
64 Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl 2013 1.21
65 Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol 2012 1.21
66 Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol 2012 1.20
67 Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int Immunol 2008 1.19
68 Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 2012 1.18
69 Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008 1.18
70 Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One 2010 1.09
71 NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol 2006 1.08
72 Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother 2008 1.08
73 Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med 2011 1.06
74 Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013 1.03
75 Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 2004 1.03
76 Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One 2010 1.03
77 Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med 2011 1.02
78 Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 2014 1.01
79 Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther 2013 1.00
80 A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations. J Nucl Med 2011 1.00
81 Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother 2010 0.99
82 Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol Immunother 2007 0.98
83 Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med 2011 0.98
84 Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med 2013 0.95
85 Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol 2006 0.95
86 Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol Ther 2007 0.93
87 Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One 2012 0.92
88 Immunotherapy of hepatocellular carcinoma. Expert Opin Biol Ther 2002 0.91
89 MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol 2010 0.90
90 CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol 2008 0.90
91 siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol 2010 0.90
92 The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother 2010 0.88
93 Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med 2012 0.87
94 Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther 2005 0.86
95 Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol Immunother 2008 0.86
96 Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol 2007 0.86
97 Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol 2013 0.85
98 PET imaging of cancer immunotherapy. J Nucl Med 2008 0.85
99 New drug targets in metastatic melanoma. J Pathol 2014 0.85
100 Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother 2013 0.84
101 Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. Histopathology 2013 0.84
102 Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One 2013 0.83
103 A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer 2010 0.83
104 BRAF-targeted therapy and immune responses to melanoma. Oncoimmunology 2013 0.82
105 Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Control Clin Trials 2004 0.82
106 Therapeutic cancer vaccines. Surg Oncol Clin N Am 2007 0.81
107 Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res 2011 0.81
108 Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin Dermatol 2009 0.81
109 CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother 2010 0.80
110 Reply to K.S. Wilson et al. J Clin Oncol 2013 0.80
111 Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med 2014 0.80
112 Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res 2014 0.79
113 Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer 2013 0.79
114 Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling. Future Oncol 2010 0.78
115 Cancer therapy: Tumours switch to resist. Nature 2012 0.78
116 Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 2017 0.78
117 Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma. Pigment Cell Melanoma Res 2010 0.77
118 Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015 0.77
119 Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Mol Immunol 2006 0.77
120 New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. Cancer J 2017 0.76
121 Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? J Clin Oncol 2009 0.76
122 Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2015 0.76
123 Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res 2010 0.76
124 Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell Melanoma Res 2009 0.76
125 Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 2016 0.75
126 Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Eur Urol 2009 0.75
127 Metastatic melanoma to the kidney presenting with renal vein tumor thrombus. Urology 2007 0.75
128 Immune rejection in a humanized model of murine prostate cancer. Anticancer Res 2010 0.75
129 Q&A: Antoni Ribas on immunotherapy progress. Cancer Discov 2012 0.75
130 Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res 2017 0.75
131 Cancer Research in the 21st Century. Ann Surg 2016 0.75